Immuneering (IMRX) Corporation announced the formation of its Pancreatic Cancer Advisory Board. The Company’s Pancreatic Cancer Advisory Board includes the following members: Tanios Bekaii-Saab, M.D., Vincent Chung, M.D., FACP, Shubham Pant, M.D., Jordan Berlin, M.D., FASCO.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IMRX:
- Immuneering to present data from Phase 2a trial of IMM-1-104 in early January
- Immuneering downgraded to Underweight from Equal Weight at Morgan Stanley
- Immuneering granted FDA Fast Track designation for IMM-1-104
- Immuneering Corp. Reports Q3 Loss, Highlights Progress
- Immuneering reports Q3 EPS (49c), consensus (55c)